OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT

Documenti analoghi

• OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
  di: Aurora, SK, et al.
  Pubblicazione: (2014)
• The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
  di: Silberstein, S, et al.
  Pubblicazione: (2013)
• OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
  di: Diener, HC, et al.
  Pubblicazione: (2013)
• Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
  di: Silberstein, Stephen D, et al.
  Pubblicazione: (2015)
• Headache symptoms of the PREEMPT population
  di: Dodick, DW, et al.
  Pubblicazione: (2013)